ZA953440B - Bifunctional protein ppeparation and use - Google Patents
Bifunctional protein ppeparation and useInfo
- Publication number
- ZA953440B ZA953440B ZA953440A ZA953440A ZA953440B ZA 953440 B ZA953440 B ZA 953440B ZA 953440 A ZA953440 A ZA 953440A ZA 953440 A ZA953440 A ZA 953440A ZA 953440 B ZA953440 B ZA 953440B
- Authority
- ZA
- South Africa
- Prior art keywords
- sub
- hinge region
- zeta
- bifunctional protein
- joined
- Prior art date
Links
- 230000001588 bifunctional effect Effects 0.000 title abstract 3
- 102000004169 proteins and genes Human genes 0.000 title abstract 3
- 108090000623 proteins and genes Proteins 0.000 title abstract 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 2
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000001086 cytosolic effect Effects 0.000 abstract 1
- 231100000433 cytotoxic Toxicity 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- 210000004698 lymphocyte Anatomy 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP94810244 | 1994-05-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA953440B true ZA953440B (en) | 1995-11-02 |
Family
ID=8218248
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA953440A ZA953440B (en) | 1994-05-02 | 1995-04-28 | Bifunctional protein ppeparation and use |
Country Status (18)
Country | Link |
---|---|
US (1) | US6984382B1 (xx) |
EP (1) | EP0758394B1 (xx) |
JP (1) | JP3742103B2 (xx) |
KR (1) | KR100373813B1 (xx) |
AT (1) | ATE228166T1 (xx) |
AU (1) | AU694222B2 (xx) |
CA (1) | CA2188422C (xx) |
DE (1) | DE69528894T2 (xx) |
DK (1) | DK0758394T3 (xx) |
ES (1) | ES2185705T3 (xx) |
FI (1) | FI119191B (xx) |
IL (1) | IL113530A0 (xx) |
NO (1) | NO316923B1 (xx) |
NZ (1) | NZ285395A (xx) |
PT (1) | PT758394E (xx) |
TW (1) | TW428026B (xx) |
WO (1) | WO1995030014A1 (xx) |
ZA (1) | ZA953440B (xx) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT758394E (pt) | 1994-05-02 | 2003-04-30 | Bernd Groner | Proteina bifuncional sua preparacao e utilizacao |
EP0870040A2 (en) * | 1995-12-29 | 1998-10-14 | Chiron Corporation | Gene delivery vehicle-targeting ligands |
AU4373197A (en) * | 1996-09-19 | 1998-04-14 | Diagnocure Inc. | Recombinant single chain antibodies directed against the gp54 cancer marker, composition comprising same and use thereof |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
DE10121113A1 (de) * | 2001-04-28 | 2002-10-31 | Gabriele Pecher | Genmodifizierte YT Zelllinie und ihre Verwendung |
ATE443084T1 (de) | 2004-07-10 | 2009-10-15 | Fox Chase Cancer Ct | Genetisch modifizierte, menschliche, natürliche killerzellenlinien: |
US7994298B2 (en) | 2004-09-24 | 2011-08-09 | Trustees Of Dartmouth College | Chimeric NK receptor and methods for treating cancer |
WO2007014278A2 (en) | 2005-07-25 | 2007-02-01 | Trubion Pharmaceuticals, Inc. | B-cell reduction using cd37-specific and cd20-specific binding molecules |
WO2007146968A2 (en) * | 2006-06-12 | 2007-12-21 | Trubion Pharmaceuticals, Inc. | Single-chain multivalent binding proteins with effector function |
US20100105136A1 (en) * | 2006-10-09 | 2010-04-29 | The General Hospital Corporation | Chimeric t-cell receptors and t-cells targeting egfrviii on tumors |
CN102099377A (zh) | 2008-04-11 | 2011-06-15 | 新兴产品开发西雅图有限公司 | Cd37免疫治疗剂及其与双功能化学治疗剂的联合 |
WO2011059836A2 (en) | 2009-10-29 | 2011-05-19 | Trustees Of Dartmouth College | T cell receptor-deficient t cell compositions |
US9273283B2 (en) | 2009-10-29 | 2016-03-01 | The Trustees Of Dartmouth College | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
NO3012268T3 (xx) | 2010-09-08 | 2018-04-14 | ||
MX347078B (es) | 2010-12-09 | 2017-04-10 | Univ Pennsylvania | Uso de celulas t modificadas por receptor de antigeno quimerico para tratar cancer. |
WO2013033626A2 (en) | 2011-08-31 | 2013-03-07 | Trustees Of Dartmouth College | Nkp30 receptor targeted therapeutics |
CN104395344B (zh) | 2012-05-07 | 2019-08-13 | 达特茅斯大学理事会 | 抗b7-h6抗体、融合蛋白及其使用方法 |
EP2958942B1 (en) | 2013-02-20 | 2020-06-03 | Novartis AG | Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells |
CN105358576B (zh) | 2013-02-20 | 2020-05-05 | 诺华股份有限公司 | 使用人源化抗EGFRvIII嵌合抗原受体治疗癌症 |
US9745368B2 (en) | 2013-03-15 | 2017-08-29 | The Trustees Of The University Of Pennsylvania | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
CA2931684C (en) | 2013-12-19 | 2024-02-20 | Novartis Ag | Human mesothelin chimeric antigen receptors and uses thereof |
US10287354B2 (en) | 2013-12-20 | 2019-05-14 | Novartis Ag | Regulatable chimeric antigen receptor |
US11028143B2 (en) | 2014-01-21 | 2021-06-08 | Novartis Ag | Enhanced antigen presenting ability of RNA CAR T cells by co-introduction of costimulatory molecules |
KR102487608B1 (ko) | 2014-04-07 | 2023-01-12 | 노파르티스 아게 | 항-cd19 키메라 항원 수용체를 사용한 암의 치료 |
BR112017000939A2 (pt) | 2014-07-21 | 2017-11-14 | Novartis Ag | tratamento de câncer usando um receptor antigênico quimérico de cll-1 |
KR102612313B1 (ko) | 2014-07-21 | 2023-12-12 | 노파르티스 아게 | 인간화 항-bcma 키메라 항원 수용체를 사용한 암의 치료 |
CN112481283A (zh) | 2014-07-21 | 2021-03-12 | 诺华股份有限公司 | 使用cd33嵌合抗原受体治疗癌症 |
US11542488B2 (en) | 2014-07-21 | 2023-01-03 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
JP7084138B2 (ja) | 2014-08-19 | 2022-06-14 | ノバルティス アーゲー | 癌処置に使用するための抗cd123キメラ抗原受容体(car) |
CN114621969A (zh) | 2014-09-17 | 2022-06-14 | 诺华股份有限公司 | 用于过继免疫疗法的具有嵌合受体的靶向细胞毒性细胞 |
AU2015330898B2 (en) | 2014-10-08 | 2022-03-10 | Novartis Ag | Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof |
EP3240803B1 (en) | 2014-12-29 | 2021-11-24 | Novartis AG | Methods of making chimeric antigen receptor-expressing cells |
WO2016115482A1 (en) | 2015-01-16 | 2016-07-21 | Novartis Pharma Ag | Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor |
WO2016126608A1 (en) | 2015-02-02 | 2016-08-11 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
CN114958764A (zh) | 2015-04-08 | 2022-08-30 | 诺华股份有限公司 | Cd20疗法、cd22疗法和与cd19嵌合抗原受体(car)表达细胞的联合疗法 |
EP4234685A3 (en) | 2015-04-17 | 2023-09-06 | Novartis AG | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
SG10201912978PA (en) | 2015-07-21 | 2020-02-27 | Novartis Ag | Methods for improving the efficacy and expansion of immune cells |
US11667691B2 (en) | 2015-08-07 | 2023-06-06 | Novartis Ag | Treatment of cancer using chimeric CD3 receptor proteins |
JP6905163B2 (ja) | 2015-09-03 | 2021-07-21 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | サイトカイン放出症候群を予測するバイオマーカー |
CN108367004B (zh) | 2015-09-21 | 2022-09-13 | 阿帕特夫研究和发展有限公司 | Cd3结合多肽 |
MA44140A (fr) | 2015-12-22 | 2021-05-19 | Dana Farber Cancer Inst Inc | Récepteur d'antigène chimérique (car) contre la mésothéline et anticorps contre l'inhibiteur de pd-l1 pour une utilisation combinée dans une thérapie anticancéreuse |
WO2017165683A1 (en) | 2016-03-23 | 2017-09-28 | Novartis Ag | Cell secreted minibodies and uses thereof |
AR110676A1 (es) | 2016-10-07 | 2019-04-24 | Novartis Ag | Tratamiento del cáncer utilizando receptores de antígenos quiméricos |
EP4043485A1 (en) | 2017-01-26 | 2022-08-17 | Novartis AG | Cd28 compositions and methods for chimeric antigen receptor therapy |
CN110582288A (zh) | 2017-02-28 | 2019-12-17 | 恩多塞特公司 | 用于car t细胞疗法的组合物和方法 |
AU2018237159A1 (en) | 2017-03-22 | 2019-09-05 | Intellia Therapeutics, Inc. | Compositions and methods for immunooncology |
US11779602B2 (en) | 2018-01-22 | 2023-10-10 | Endocyte, Inc. | Methods of use for CAR T cells |
EP3806962A1 (en) | 2018-06-13 | 2021-04-21 | Novartis AG | Bcma chimeric antigen receptors and uses thereof |
CN110627895B (zh) * | 2018-06-25 | 2021-03-23 | 北京大学 | 肺癌特异性tcr及其分析技术和应用 |
WO2020043899A1 (en) | 2018-08-31 | 2020-03-05 | Invectys | Chimeric antigen receptors against multiple hla-g isoforms |
TW202134285A (zh) | 2019-11-26 | 2021-09-16 | 瑞士商諾華公司 | Cd19和cd22嵌合抗原受體及其用途 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE260880T1 (de) | 1986-09-11 | 1988-11-03 | Dana-Farber Cancer Institute, Inc., Boston, Mass., Us | Verfahren zur ausloesung der zytotoxizitaet. |
JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク,インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
FI105320B (fi) | 1988-04-04 | 2000-07-31 | Oncogen | Menetelmä vasta-aineheterokonjugaattien valmistamiseksi, joita käytetään imusoluaktiivisuuden säätelyssä ja diagnoosissa |
EP0568537B1 (en) | 1990-10-31 | 1998-02-04 | Somatix Therapy Corporation | Genetic modification of endothelial cells |
CA2074825C (en) * | 1990-12-14 | 2005-04-12 | Daniel J. Capon | Chimeric chains for receptor-associated signal transduction pathways |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
AU662311B2 (en) * | 1991-02-05 | 1995-08-31 | Novartis Ag | Recombinant antibodies specific for a growth factor receptor |
FR2672901B1 (fr) | 1991-02-15 | 1994-09-30 | Immunotech Sa | Nouvelles molecules de dna recombinants codant pour une chaine du recepteur pour l'antigene des cellules t, procede de preparation, anticorps et medicaments les renfermant. |
AU1453792A (en) | 1991-02-27 | 1992-10-06 | Regents Of The University Of California, The | Targeting complex mediated immunogenicity |
IE920716A1 (en) | 1991-03-07 | 1992-09-09 | Gen Hospital Corp | Redirection of cellular immunity by receptor chimeras |
US5939531A (en) | 1991-07-15 | 1999-08-17 | Novartis Corp. | Recombinant antibodies specific for a growth factor receptor |
WO1993019163A1 (en) * | 1992-03-18 | 1993-09-30 | Yeda Research And Development Co, Ltd. | Chimeric receptor genes and cells transformed therewith |
CA2118026A1 (en) | 1992-04-14 | 1993-10-28 | Guy T. Layton | Induction of ctl responses |
PT758394E (pt) | 1994-05-02 | 2003-04-30 | Bernd Groner | Proteina bifuncional sua preparacao e utilizacao |
-
1995
- 1995-04-20 PT PT95918576T patent/PT758394E/pt unknown
- 1995-04-20 NZ NZ285395A patent/NZ285395A/xx not_active IP Right Cessation
- 1995-04-20 ES ES95918576T patent/ES2185705T3/es not_active Expired - Lifetime
- 1995-04-20 AU AU24469/95A patent/AU694222B2/en not_active Ceased
- 1995-04-20 JP JP52796595A patent/JP3742103B2/ja not_active Expired - Fee Related
- 1995-04-20 EP EP95918576A patent/EP0758394B1/en not_active Expired - Lifetime
- 1995-04-20 WO PCT/EP1995/001494 patent/WO1995030014A1/en active IP Right Grant
- 1995-04-20 AT AT95918576T patent/ATE228166T1/de active
- 1995-04-20 CA CA2188422A patent/CA2188422C/en not_active Expired - Lifetime
- 1995-04-20 KR KR1019960706165A patent/KR100373813B1/ko not_active IP Right Cessation
- 1995-04-20 DE DE69528894T patent/DE69528894T2/de not_active Expired - Lifetime
- 1995-04-20 DK DK95918576T patent/DK0758394T3/da active
- 1995-04-24 TW TW084103999A patent/TW428026B/zh active
- 1995-04-28 ZA ZA953440A patent/ZA953440B/xx unknown
- 1995-04-28 IL IL11353095A patent/IL113530A0/xx not_active IP Right Cessation
-
1996
- 1996-10-25 FI FI964311A patent/FI119191B/fi not_active IP Right Cessation
- 1996-11-01 NO NO19964641A patent/NO316923B1/no not_active IP Right Cessation
-
2000
- 2000-06-19 US US09/596,774 patent/US6984382B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP0758394B1 (en) | 2002-11-20 |
JP3742103B2 (ja) | 2006-02-01 |
DE69528894D1 (de) | 2003-01-02 |
DE69528894T2 (de) | 2003-03-27 |
FI964311A0 (fi) | 1996-10-25 |
ES2185705T3 (es) | 2003-05-01 |
WO1995030014A1 (en) | 1995-11-09 |
NZ285395A (en) | 1998-10-28 |
DK0758394T3 (da) | 2003-03-03 |
KR100373813B1 (ko) | 2003-10-08 |
ATE228166T1 (de) | 2002-12-15 |
CA2188422A1 (en) | 1995-11-09 |
FI964311A (fi) | 1996-10-25 |
EP0758394A1 (en) | 1997-02-19 |
NO964641L (no) | 1996-11-01 |
JPH09512176A (ja) | 1997-12-09 |
NO316923B1 (no) | 2004-06-28 |
US6984382B1 (en) | 2006-01-10 |
AU2446995A (en) | 1995-11-29 |
CA2188422C (en) | 2011-03-15 |
PT758394E (pt) | 2003-04-30 |
NO964641D0 (no) | 1996-11-01 |
TW428026B (en) | 2001-04-01 |
IL113530A0 (en) | 1995-07-31 |
FI119191B (fi) | 2008-08-29 |
AU694222B2 (en) | 1998-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA953440B (en) | Bifunctional protein ppeparation and use | |
IL112390A0 (en) | A cell which expresses chimeric receptors, DNA and vectors encoding said receptors and pharmaceutical compositions containing the same | |
WO2000023573A3 (en) | Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies | |
NZ333915A (en) | Soluble monovalent and multivalent MHC class II fusion proteins | |
AU6059096A (en) | CTLA4 mutant molecules and uses thereof | |
WO2002077029A3 (en) | Cd19-specific redirected immune cells | |
NZ332598A (en) | Human BAS-1 protein, and use as an antagonist for modulating physiology or development of a cell | |
DE69435261D1 (de) | Menschlicher rezeptor h4-1bb | |
NZ527297A (en) | Immunosuppression by blocking T cell co-stimulation signal 2 (B7/CD28 interaction) | |
NO934801D0 (no) | CTL4A reseptor, fusjonsproteiner som inneholder den og anvendelse derav | |
CA2312667A1 (en) | Novel cytokine | |
KR927003847A (ko) | 수용체-결합된 신호 변환 경로를 위한 키메라 사슬 | |
ES2093623T3 (es) | Receptores monovalentes y oligovalentes, bioespecificos y oligoespecificos, su preparacion y empleo. | |
AU1914795A (en) | Monoclonal antibodies specific to vegf receptors and uses thereof | |
IL104570A0 (en) | Chimeric genes and cells transformed therewith | |
GR3030415T3 (en) | Platelet activating factor antagonists. | |
AU1868695A (en) | Immuno-stimulatory monoclonal antibodies | |
WO1996021028A3 (en) | Soluble heterodimeric t cell receptors and their antibodies | |
AU3283693A (en) | Specific antibodies against activated platelets, the preparation thereof and the use thereof in diagnosis and therapy | |
AU2525597A (en) | Monoclonal antibodies binding human growth hormone (hgh) | |
AU2002323894A1 (en) | Costimulating t-cell polypeptide, monoclonal antibodies, their preparation and use | |
WO2001042294A3 (en) | Clasp-4 transmembrane protein | |
MX9801253A (es) | Proteinas de fusion de alergeno -xc032. | |
HUP0001579A2 (en) | Cell surface molecule mediating cell adhesion and signal transmission |